Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A00443 | Pages: 170 | Charts: 31 | Tables: 116 |
The global RNA based therapeutics market size generated $4,938.38 million in 2021, and is projected to reach $25,121.95 million by 2030, growing at a CAGR of 17.6% from 2021 to 2030. RNA based therapeutics has garnered significant attention in the recent years due to its potential to treat variety of chronic diseases such as cancer, diabetes, AIDS, tuberculosis and certain cardiovascular conditions also rare and genetic disorders. Despite being in the clinical research phase, the RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development of this therapeutics is based on promising technologies such as RNA interference technology (RNAi), antisense technology and SMaRT technology. RNAi technology and antisense technology together are gaining prominence in the research industry, as these technologies provide base sequence to develop RNA drugs.
Get more information on this report : Request Sample Pages
RNAi technology works by causing destruction of specific mRNA molecules, whereas antisense technology works by synthesizing strand of RNA from known gene sequence. These newly synthesized RNA strands then bind to mRNA and makes mRNA inactive. Gene silencing potential of RNA based therapeutics is the primary driver for the growth of this market. The other drivers include target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, critical issues in drug delivery, high cost of research, and high failure rates are some of the major hurdles for the companies working in this field. Despite the restraints, RNA based therapeutics has the potential to grow due to increasing interest exhibited by the pharmaceutical industries for the commercialization of these therapies.
The RNA based therapeutics market is segmented on the basis of type, application, end user and region. Based on type, the market is segmented into RNA interference (RNAi) technologies and RNA antisense technologies. Based on application, the market is segmented into genetic disorders and auto immune disorders. Based on end user, the RNA based therapeutics market is segmented into research institutes, and hospitals & clinics. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans.
After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement.
Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, only a few vaccines that received emergency approvals for COVID-19 prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns.
Almost every nation is dealing with the outbreak. Most markets are experiencing a decline, owing to the outbreak. The COVID-19 pandemic is an unprecedented global public health challenge and is anticipated to have a negative impact on the RNA based therapeutics market, mRNA vaccines could potentially provide long-term solutions all over the world for diseases ranging from influenza to AIDS, but due to lockdown and temporary closure of research institutes and academic research, the RNA based therapeutics has decreased. Due to lockdowns and stay-at-home orders, people’s lifestyles have become even more sedentary and worse than before, public health recommendation i.e., closure of small laboratories and research centers to prevent SARS-COV-2 spread have the potential to reduce RNA based therapeutics research. The results shed light on the financial fragility of many RNA based therapeutics key players companies.
Depending on type, the market is divided into RNA interference (RNAi) and RNA antisense. RNA antisense segment is projected to witness fastest growth during the forecast period, owing to increase in revenue of RNA antisense drug discovery and therapeutics.
[TYPEGRAPH]
Get more information on this report : Request Sample Pages
By application, the RNA based therapeutics market is segmented into genetic disorders and auto immune disorders. Genetic disorders segment accounted for a majority of market share in the global RNA based therapeutics market in 2020 and expected to remain dominant during the forecast period, owing to surge in case of genetic diseases, rare disorders, and molecular diagnostics. These factors are expected to further fuel the demand for RNA based therapeutic.
[APPLICATIONGRAPH]
Get more information on this report : Request Sample Pages
End User Segment Review
Depending on end user, the market is categorized into research institutes, and hospitals & clinics. The research institutes segment is projected to show fastest growth during the forecast period, due to the collaboration of research organizations and academic research institutes or collaborating with government bodies to bear the high cost of research.
[ENDUSERGRAPH]
Get more information on this report : Request Sample Pages
By region, the RNA based therapeutics market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America dominated the market in 2020, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. The research activities for RNA-based therapeutics are rising in North America due to significant infrastructure for developmental research, availability of substantial research funds and growing government initiatives toward RNA based therapeutics are anticipated to drive the RNA based therapeutics market growth.
[REGIONGRAPH]
Get more information on this report : Request Sample Pages
This report provides comprehensive competitive analysis and profiles of prominent RNA based therapeutics market players such as Alnylam Pharmaceuticals, Inc., Silence Therapeutics plc, Arbutus Biopharma Corporation, Genzyme (Sanofi), Ionis Pharmaceuticals, Sarepta Therapeutics, Benitec Biopharma Inc., Arrowhead Pharmaceuticals, Biogen, Inc. and Gradalis, Inc.
Key Benefits for Stakeholders
Key Market Segments
Key Market Players
CHAPTER 1- INTRODUTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Key Players
1.5.Research methodology
1.5.1.Secondary research
1.5.2.Primary research
1.5.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning, 2020
3.4.Porter’s five forces analysis
3.4.1.Bargaining power of suppliers
3.4.2.Bargaining power of buyers
3.4.3.Threat of new entrants
3.4.4.Threat of substitutes
3.4.5.Intensity of competitive rivalry
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Target Specificity and Selectivity of Treatment
3.5.1.2.Initiatives From Government for Large-Scale Sequencing Projects
3.5.2.Restraints
3.5.2.1.Hurdles In Drug Delivery
3.5.2.2.High Cost of Research and Threat of Failure
3.5.3.Opportunities
3.5.3.1.Early Commercialization of Pipeline Therapeutics Assists to Gain Competitive Advantage
3.5.3.2.Multifactorial Disease Targeting
3.5.4.Impact Analysis
3.1.COVID-19 impact analysis on the RNA based therapeutics market
CHAPTER 4:RNA BASED THERAPEUTICS MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast, by Type
4.2.RNA Interference (RNAi)
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.RNA Antisense
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
CHAPTER 5:RNA BASED THERAPEUTICS MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast, by end user
5.2.Genetic Disorders
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Auto immune disorders
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
CHAPTER 6:RNA BASED THERAPEUTICS MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast, by end user
6.2.Research Institutes
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Hospitals & Clinics
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
CHAPTER 7:RNA BASED THERAPEUTICS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast, by region
7.2.North America
7.2.1.Key trends and growth opportunities
7.2.2.Market size and forecast, by type
7.2.3.Market size and forecast, by application
7.2.4.Market size and forecast, by end user
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.2.U.S. market size and forecast, by type
7.2.6.Market size and forecast, by application
7.2.6.1.U.S. market size and forecast, by end user
7.2.6.2.Canada
7.2.6.3.Canada market size and forecast, by type
7.2.6.4.Canada market size and forecast, by application
7.2.6.5.Canada market size and forecast, by end user
7.2.6.6.Mexico
7.2.6.7.Mexico market size and forecast, by type
7.2.6.8.Mexico market size and forecast, by application
7.2.6.9.Mexico market size and forecast, by end user
7.3.Europe
7.3.1.Key trends and growth opportunities
7.3.2.Market size and forecast, by type
7.3.3.Market size and forecast, by application
7.3.4.Market size and forecast, by end user
7.3.5.Market size and forecast, by country
7.3.5.1.Germany.
7.3.5.2.Germany market size and forecast, by type
7.3.5.3.Germany market size and forecast, by application
7.3.5.4.Germany market size and forecast, by end user
7.3.5.5.France
7.3.5.6.France market size and forecast, by type
7.3.5.7.France market size and forecast, by application
7.3.5.8.France market size and forecast, by end user
7.3.5.9.UK
7.3.5.10.UK market size and forecast, by type
7.3.5.11.UK market size and forecast, by application
7.3.5.12.UK market size and forecast, by end user
7.3.5.13.Italy
7.3.5.14.Italy market size and forecast, by type
7.3.5.15.Italy market size and forecast, by application
7.3.5.16.Italy market size and forecast, by end user
7.3.5.17.Spain
7.3.5.18.Spain market size and forecast, by type
7.3.5.19.Spain market size and forecast, by application
7.3.5.20.Spain market size and forecast, by end user
7.3.5.21.Rest of Europe
7.3.5.22.Rest of Europe market size and forecast, by type
7.3.5.23.Rest of Europe market size and forecast, by application
7.3.5.24.Rest of Europe market size and forecast, by end user
7.4.Asia-Pacific
7.4.1.Key trends and growth opportunities
7.4.2.Market size and forecast, by type
7.4.3.Market size and forecast, by application
7.4.4.Market size and forecast, by end user
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.2.Japan market size and forecast, by type
7.4.5.3.Japan market size and forecast, by application
7.4.5.4.Japan market size and forecast, by end user
7.4.5.5.China
7.4.5.6.China market size and forecast, by type
7.4.5.7.China market size and forecast, by application
7.4.5.8.China market size and forecast, by end user
7.4.5.9.India
7.4.5.10.India market size and forecast, by type
7.4.5.11.India market size and forecast, by application
7.4.5.12.India market size and forecast, by end user
7.4.5.13.Australia
7.4.5.14.Australia market size and forecast, by type
7.4.5.15.Australia market size and forecast, by application
7.4.5.16.Australia market size and forecast, by end user
7.4.5.17.South Korea
7.4.5.18.South Korea market size and forecast, by type
7.4.5.19.South Korea market size and forecast, by application
7.4.5.20.South Korea market size and forecast, by end user
7.4.5.21.Rest of Asia-Pacific
7.4.5.22.Rest of Asia-Pacific market size and forecast, by type
7.4.5.23.Rest of Asia-Pacific market size and forecast, by application
7.4.5.24.Rest of Asia-Pacific market size and forecast, by end user
7.5.LAMEA
7.5.1.Key trends and opportunities
7.5.2.Market size and forecast, by type
7.5.3.Market size and forecast, by application
7.5.4.Market size and forecast, by end user
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.2.Brazil market size and forecast, by type
7.5.5.3.Brazil market size and forecast, by application
7.5.5.4.Brazil market size and forecast, by end user
7.5.5.5.Saudi Arabia
7.5.5.6.Saudi Arabia market size and forecast, by type
7.5.5.7.Saudi Arabia market size and forecast, by application
7.5.5.8.Saudi Arabia market size and forecast, by end user
7.5.5.9.South Africa
7.5.5.10.South Africa market size and forecast, by type
7.5.5.11.South Africa market size and forecast, by application
7.5.5.12.South Africa market size and forecast, by end user
7.5.5.13.Rest of LAMEA
7.5.5.14.Rest of LAMEA market size and forecast, by type
7.5.5.15.Rest of LAMEA market size and forecast, by application
7.5.5.16.Rest of LAMEA market size and forecast, by end user
CHAPTER 8:COMPANY PROFILES
8.1.Alnylam Pharmaceuticals Inc
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.Arbutus Biopharma Corporation
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.3.Arrowhead Pharmaceuticals
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.Benitec Biopharma Inc.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.Biogen
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.Gradalis, Inc.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segment
8.6.4.Product portfolio
8.7.Genzyme (Sanofi), Inc.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.Ionis Pharmaceuticals, Inc.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.Sarepta Therapeutics
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.Silence Therapeutics plc
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
LIST OF TABLES
TABLE 01.RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030($MILLION)
TABLE 02.RNA BASED THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI), BY REGION, 2020–2030($MILLION)
TABLE 03.RNA BASED THERAPEUTICS MARKET FOR RNA ANTISENSE, BY REGION, 2020–2030($MILLION)
TABLE 04.RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 05.RNA BASED THERAPEUTICS MARKET FOR GENETIC DISORDERS, BY REGION, 2020–2030 ($MILLION)
TABLE 06.RNA BASED THERAPEUTICS MARKET FOR AUTO IMMUNE DISORDERS, BY REGION, 2020–2030($MILLION)
TABLE 07.RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030($MILLION)
TABLE 08.RNA BASED THERAPEUTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020–2030($MILLION)
TABLE 09.RNA BASED THERAPEUTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2030 ($MILLION)
TABLE 10.RNA BASED THERAPEUTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 11.NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 12.NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 13.NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 14.NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 15.U.S. RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 16.U.S. RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 17.U.S. RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 18.CANADA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 19.CANADA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 20.CANADA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 21.MEXICO RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 22.MEXICO RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 23.MEXICO RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 24.EUROPE RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 25.EUROPE RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 26.EUROPE RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 27.EUROPE RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 28.GERMANY RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 29.GERMANY RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 30.GERMANY RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 31.FRANCE RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 32.FRANCE RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 33.FRANCE RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 34.UK RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 35.UK RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 36.UK RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 37.ITALY RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 38.ITALY RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 39.ITALY RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 40.SPAIN RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 41.SPAIN RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 42.SPAIN RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 43.REST OF EUROPE RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 44.REST OF EUROPE RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 45.REST OF EUROPE RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 46.ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 47.ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 48.ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 49.ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 50.JAPAN RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 51.JAPAN RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 52.JAPAN RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 53.CHINA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 54.CHINA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 55.CHINA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 56.INDIA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 57.INDIA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 58.INDIA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 59.AUSTRALIA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 60.AUSTRALIA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 61.AUSTRALIA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 62.SOUTH KOREA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 63.SOUTH KOREA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 64.SOUTH KOREA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 65.REST OF ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 66.REST OF ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 67.REST OF ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 68.LAMEA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 69.LAMEA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 70.LAMEA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 71.LAMEA RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 72.BRAZIL RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 73.BRAZIL RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 74.BRAZIL RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 75.SAUDI ARABIA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 76.SAUDI ARABIA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 77.SAUDI ARABIA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 78.SOUTH AFRICA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 79.SOUTH AFRICA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 80.SOUTH AFRICA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 81.REST OF LAMEA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 82.REST OF LAMEA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 83.REST OF LAMEA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 84.ALNYLAM: COMPANY SNAPSHOT
TABLE 85.ALNYLAM: OPERATING SEGMENTS
TABLE 86.ALNYLAM: PRODUCT PORTFOLIO
TABLE 87.ALNYLAM.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 88.ARBUTUS: COMPANY SNAPSHOT
TABLE 89.ARBUTUS SEGMENTS
TABLE 90.ARBUTUS: PRODUCT PORTFOLIO
TABLE 91.ARROWHEAD: COMPANY SNAPSHOT
TABLE 92.ARROWHEAD: OPERATING SEGMENT
TABLE 93.ARROWHEAD: PRODUCT PORTFOLIO
TABLE 94.BENITEC: COMPANY SNAPSHOT
TABLE 95.BENITEC: OPERATING SEGMENTS
TABLE 96.BENITEC: PRODUCT PORTFOLIO
TABLE 97.BIOGEN: COMPANY SNAPSHOT
TABLE 98.BIOGEN: OPERATING SEGMENTS
TABLE 99.BIOGEN: PRODUCT PORTFOLIO
TABLE 100.GRADALIS: COMPANY SNAPSHOT
TABLE 101.GRADALIS: OPERATING SEGMENT
TABLE 102.GRADALIS: PRODUCT PORTFOLIO
TABLE 103.GENZYME: COMPANY SNAPSHOT
TABLE 104.GENZYME: OPERATING SEGMENTS
TABLE 105.SANOFI: PRODUCT PORTFOLIO
TABLE 106.SANOFI.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107.IONIS: COMPANY SNAPSHOT
TABLE 108.IONIS: OPERATING SEGMENTS
TABLE 109.IONIS: PRODUCT PORTFOLIO
TABLE 110.SAREPTA: COMPANY SNAPSHOT
TABLE 111.SAREPTA: OPERATING SEGMENT
TABLE 112.SAREPTA: PRODUCT PORTFOLIO
TABLE 113.SAREPTA.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114.SILENCE: COMPANY SNAPSHOT
TABLE 115.SILENCE OPERATING SEGMENTS
TABLE 116.SILENCE: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.RNA BASED THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES: BY DEVELOPMENT, 2018-2021 (%)
FIGURE 04.TOP WINNING STRATEGIES: BY DEVELOPMENT, 2018-2021 (%)
FIGURE 05.TOP INVESTMENT POCKETS WINNING STRATEGIES: BY COMPANY, 2018-2021 (%)
FIGURE 06.TOP PLAYER POSITIONING, 2020
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.HIGH BARGAINING POWER OF BUYERS
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE THREAT OF SUBSTITUTES
FIGURE 11.MODERATR INTENSITY OF COMPETITIVE RIVALRY
FIGURE 12.IMPACT ANALYSES, RNA BASED THERAPEUTICS MARKET
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR RNA ANTISENSE BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR GENETIC DISORDERS BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR AUTO IMMUNE DISORDERS BY COUNTRY, 2020 & 2030 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR RESEARCH INSTITUTES BY COUNTRY, 2020 & 2030 (%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR HOSPITALS & CLINICS BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.ALNYLAM: NET SALES, 2018–2020 ($MILLION)
FIGURE 20.ALNYLAM: REVENUE SHARE BY REGION, 2020(%)
FIGURE 21.ARBUTUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.ARROWHEAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 23.BENITEC: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.BIOGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 25.BIOGEN: REVENUE SHARE BY REGION, 2020(%)
FIGURE 26.GENZYME: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.GENZYME: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 28.GENZYME: REVENUE SHARE BY REGION, 2020(%)
FIGURE 29.IONIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.IONIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.SAREPTA: NET SALES, 2018–2020 ($MILLION)